Vas Narasimhan's 'Wild Card' drugs: Novartis CEO highlights potential jackpots, as well as late-stage stars, in R&D presentation
Novartis is always one of the industry’s biggest R&D spenders. As they often do toward the end of each year, company execs are highlighting the drugs they expect will most likely be winners in 2021.
And they’re also dreaming about some potential big-time lottery tickets.
As part of its annual investor presentation Tuesday, where the company allows investors and analysts to virtually schmooze with the bigwigs, Novartis CEO Vas Narasimhan will outline what he thinks are the pharma’s “Wild Cards.” The slate of five experimental drugs are those that Novartis hopes can be high-risk, high-reward entrants into the market over the next half-decade or so, and cover a wide range of indications.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.